Serum relaxin levels in subjects with multiple sclerosis

Area of Science:

• Neuroimmunology
• Endocrinology

Background:

• Multiple Sclerosis (MS) is a chronic, inflammatory, auto-immune neurodegenerative disease affecting the central nervous system.
• MS is a leading cause of disability in young and middle-aged adults, with over 2.5 million cases globally.
• Current MS therapies offer modest benefits and significant side effects, necessitating novel therapeutic targets.

Purpose of the Study:

• To investigate the role of relaxin, a hormone known for its function in pregnancy, in the context of Multiple Sclerosis.
• To explore the potential link between relaxin levels, inflammation, and immune dysregulation in MS.

Main Methods:

• Serum relaxin levels were measured in subjects diagnosed with Multiple Sclerosis.
• The study considered the known mechanisms of relaxin, including its influence on glucocorticoid receptors, adrenocorticotropic hormone, and peroxisome proliferator-activated receptor gamma.

Main Results:

• Serum relaxin levels were found to be significantly elevated in individuals with Multiple Sclerosis.
• The study suggests that decreased relaxin receptor binding may lead to a negative feedback loop, contributing to elevated relaxin levels.

Conclusions:

• Elevated serum relaxin in MS patients suggests its involvement in the disease's inflammatory and immune pathology.
• Dysregulation of the relaxin system, potentially due to reduced receptor binding, may contribute to the pathogenesis of Multiple Sclerosis.